New solutions for aptamer applications in Europe

7 August 2015  •  Author: Eurogentec

Eurogentec s.a. and NeoVentures Biotechnology Inc. are pleased to announce that they have entered into a business alliance to stimulate the development of aptamer applications in Europe.

As part of this agreement Eurogentec has agreed to provide NeoVentures clients with discounted pricing on their aptamer synthesis needs. Eurogentec is a Belgian based company that has developed a global reputation for their commitment to quality synthesis of oligonucleotides for life science research and in vitro diagnostics. NeoVentures is a Canadian company which has established global leadership in the development of aptamer based diagnostics. Both companies see a bright future for aptamer applications. This agreement is intended to help nurture the commercial development of all forms of aptamer applications throughout Europe.

Comments are closed.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...